Disclosure in terms of Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) ("SAST") Regulations, 2015.

Novartis India Limited July 29, 2026 The Secretary BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 500 672 Subject: Disclosure in terms of Regulation 29 (2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) (“SAST”) Regulations, 2015 Dear Sir/ Madam, Pursuant to Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and as amended from time to time, please find enclosed herewith the disclosure regarding the sale of equity shares of Novartis India Limited ("the Company"). This disclosure is filed in connection with the sale of 1,74,50,680 (One Crore Seventy-Four Lakhs Fifty Thousand Six Hundred and Eighty Only) equity shares (representing 70.68% (Seventy point Sixty-Eight) of the total share capital) by Novartis AG on Wednesday, July 29, 2026. Kindly take the above information on record and acknowledge receipt. The disclosure will also be made available on the Company’s website at www.nilpharma.co.in. Yours sincerely, For Novartis India Limited Chandni Maru Company Secretary and Compliance Officer A60291 Encl as above: Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in Novartis AG CH-4002 Basel Switzerland https://www.novartis.com https://x.com/novartisnews July 29, 2026 1. The Secretary, BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001 Maharashtra, India 2. The Board of Directors, Novartis India Limited Inspire BKC, 7th Floor, Bandra Kurla Complex, Bandra East, Mumbai 400 051, Maharashtra, India. Scrip Code: 500672 Sub : Disclosure under Regulation 29 (2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Dear Sir / Ma’am: We, Novartis AG, hereby make this disclosure pursuant to Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. We request you to kindly take the above on record and acknowledge receipt. [Signature pages follow] Novartis AG CH-4002 Basel Switzerland https://www.novartis.com https://x.com/novartisnews Disclosures under Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 read with SEBI Master circular SEBI/HO/CFD/PoD-1/P/CIR/2023/31 dated February 16, 2023 Name of the Target Company (TC) Novartis India Limited (“Target Company”) Name(s) of the Seller Novartis AG (“Seller”) Whether the Seller belongs to Yes, the Seller was the promoter of the Target Company. Promoter/Promoter group However, pursuant to the completion of the present sale of the equity shares of the Target Company, the Seller has ceased to hold any equity shares of the Target Company and stands reclassified from ‘promoter’ to ‘public’ category shareholder of the Target Company in accordance with Regulation 31A(10) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Name(s) of the Stock Exchange(s) where BSE Limited the shares of TC are Listed Details of the acquisition / disposal as Number % w.r.t.total % w.r.t. total diluted follows share/voting capital share/voting capital wherever of the TC (**) applicable(*) Before the sale under consideration, holding of : a) Shares carrying voting rights 1,74,50,680 70.68% 70.68% b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others) c) Voting rights (VR) otherwise than by shares d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) e) Total (a+b+c+d) 1,74,50,680 70.68% 70.68% Details of acquisition/sale a) Shares carrying voting rights 1,74,50,680 70.68% 70.68% acquired/sold b) VRs acquired /sold otherwise than by shares c) Warrants/convertible securities/any other instrument that entitles the Novartis AG CH-4002 Basel Switzerland https://www.novartis.com https://x.com/novartisnews acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold 1,74,50,680 70.68% 70.68% d) Shares encumbered / invoked/released by the acquirer e) Total (a+b+c+/-d) After the acquisition/sale, holding of: a) Shares carrying voting rights NIL NIL NIL b) Shares encumbered with the acquirer c) VRs otherwise than by shares d) Warrants/convertible securities/any other instrument that entitles the NIL NIL NIL acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition e) Total (a+b+c+d) Mode of acquisition / sale (e.g. open Off market sale pursuant to the Agreement for the sale market / off-market / public issue / rights and purchase of the Sale Shares in Novartis India issue / preferential allotment / inter-se Limited dated February 19, 2026. transfer etc). Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of Wednesday, shares, whichever is applicable July 29, 20 26 Equity share capital / total voting capital of INR 12,34,53,985 comprising of 2,46,90,797 fully paid-up the TC before the said acquisition / sale equity shares of face value of INR 5 each Equity share capital/ total voting capital of INR 12,34,53,985 comprising of 2,46,90,797 fully paid- the TC after the said acquisition / sale up equity shares of face value of INR 5 each Total diluted share/voting capital of the TC INR 12,34,53,985 comprising of 2,46,90,797 fully paid- after the said acquisition / sale up equity shares of face value of INR 5 each Note: (*) Total share capital/ voting capital to be taken as per the latest filing done by the Target Company to the Stock Exchange under Clause 35 of the listing Agreement or Regulation 31 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. (**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC. [Signature pages follow]